Active Filter(s):
Details:
Funding will help advance Gliknik clinical and pre-clinical programs, including: A randomized double-blind, placebo-controlled phase 2 study of Gliknik immuno-oncology compound biropepimut-S, which is nearing completion.
Lead Product(s): Biropepimut-S,GM CSF,Cyclophosphamide
Therapeutic Area: Oncology Product Name: GL-0817
Highest Development Status: Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: First In Ventures
Deal Size: $11.5 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 24, 2021